Amoy Diagnostics Yönetim

Yönetim kriter kontrolleri 3/4

Amoy Diagnostics CEO'su Jiemin Luo, Jan2012 tarihinde atandı, in görev süresi 12.83 yıldır. şirketin hisselerinin 0.039% doğrudan sahiptir ve bu hisselerin değeri CN¥ 3.77M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 12.8 yıl ve 3.3 yıldır.

Anahtar bilgiler

Jiemin Luo

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	12.8yrs
CEO sahipliği	0.04%
Yönetim ortalama görev süresi	12.8yrs
Yönetim Kurulu ortalama görev süresi	3.3yrs

Son yönetim güncellemeleri

Recent updates

Amoy Diagnostics Co., Ltd.'s (SZSE:300685) Earnings Haven't Escaped The Attention Of Investors

Sep 18

Are Investors Undervaluing Amoy Diagnostics Co., Ltd. (SZSE:300685) By 23%?

Aug 23

Amoy Diagnostics' (SZSE:300685) Upcoming Dividend Will Be Larger Than Last Year's

May 27

Earnings Report: Amoy Diagnostics Co., Ltd. Missed Revenue Estimates By 6.1%

Apr 24

Amoy Diagnostics (SZSE:300685) Could Easily Take On More Debt

Apr 18

What Amoy Diagnostics Co., Ltd.'s (SZSE:300685) 33% Share Price Gain Is Not Telling You

Mar 02

Is Amoy Diagnostics Co., Ltd. (SZSE:300685) Worth CN¥22.0 Based On Its Intrinsic Value?

Mar 01

CEO

Jiemin Luo (41 yo)

12.8yrs

Görev süresi

CN¥676,500

Tazminat

Mr. Jiemin Luo has been General Manager of Amoy Diagnostics Co., Ltd. and served its Deputy General Manager and Secretary of The Board of Directors since January 2012. He has been Non-Independent Director...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ying Chen	CFO, Accounting Supervisor & Secretary to the Board of Directors	9.5yrs	CN¥872.70k	0.039% CN¥ 3.8m
Ruan Li	Deputy GM	16.3yrs	CN¥872.70k	0.039% CN¥ 3.8m
Frank Ron Zheng	Deputy GM & Director	3.3yrs	CN¥802.30k	Veri yok
Huibin Zheng	Deputy General Manager	no data	CN¥694.40k	0.039% CN¥ 3.8m
Jiemin Luo	GM & Director	12.8yrs	CN¥676.50k	0.039% CN¥ 3.8m
Fei Luo	Deputy GM & Director	15.3yrs	CN¥755.80k	Veri yok

12.8yrs

Ortalama Görev Süresi

46yo

Ortalama Yaş

Deneyimli Yönetim: 300685 'un yönetim ekibi deneyimli ve deneyimlidir ( 12.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ruan Li	Deputy GM	1.8yrs	CN¥872.70k	0.039% CN¥ 3.8m
Frank Ron Zheng	Deputy GM & Director	3.3yrs	CN¥802.30k	Veri yok
Jiemin Luo	GM & Director	3.3yrs	CN¥676.50k	0.039% CN¥ 3.8m
Fei Luo	Deputy GM & Director	15.3yrs	CN¥755.80k	Veri yok
Li-Mou Zheng	Chairman	16.8yrs	CN¥490.30k	Veri yok
Hongyu Wang	Chairman of Supervisory Board	9.4yrs	Veri yok	Veri yok
Xin Huang	Non-Independent Director	3.3yrs	Veri yok	Veri yok
Wenjin Su	Independent Director	3.3yrs	Veri yok	Veri yok
Enhua Wang	Independent Director	3.3yrs	CN¥112.70k	Veri yok
Qi Du	Non-Employee Supervisor	3.3yrs	Veri yok	Veri yok
Zhe Shen	Independent Director	less than a year	Veri yok	Veri yok
Qiao Wu	Independent Director	less than a year	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 300685 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.3 yıldır).

Amoy Diagnostics Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Amoy Diagnostics Co., Ltd. Elects Shen Zhe and Wu Qiao as Independent Director

Amoy Diagnostics Co., Ltd., Annual General Meeting, May 13, 2024

Less than half of directors are independent

Amoy Diagnostics Co., Ltd., Annual General Meeting, Jun 20, 2022

High number of new directors

Recent updates

Price target increased by 7.0% to CN¥28.92

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Share price stability

Amoy Diagnostics Co., Ltd. to Report Q3, 2024 Results on Oct 22, 2024

Investor sentiment improves as stock rises 35%

Amoy Diagnostics Co., Ltd.'s (SZSE:300685) Earnings Haven't Escaped The Attention Of Investors

Now 20% undervalued

Are Investors Undervaluing Amoy Diagnostics Co., Ltd. (SZSE:300685) By 23%?

Amoy Diagnostics Co., Ltd. Elects Shen Zhe and Wu Qiao as Independent Director

Now 20% undervalued after recent price drop

Second quarter 2024 earnings: Revenues and EPS in line with analyst expectations

Now 20% undervalued after recent price drop

Amoy Diagnostics Co., Ltd. to Report First Half, 2024 Results on Jul 30, 2024

Amoy Diagnostics' (SZSE:300685) Upcoming Dividend Will Be Larger Than Last Year's

Dividend increased to CN¥0.15

Amoy Diagnostics Co., Ltd. Announces Cash Dividend on A Shares for the Year 2023, Payable on 30 May 2024

Earnings Report: Amoy Diagnostics Co., Ltd. Missed Revenue Estimates By 6.1%

Amoy Diagnostics (SZSE:300685) Could Easily Take On More Debt

Full year 2023 earnings: EPS exceeds analyst expectations

Amoy Diagnostics Co., Ltd., Annual General Meeting, May 13, 2024

Amoy Diagnostics Co., Ltd. (SZSE:300685) commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on February 26, 2024.

Amoy Diagnostics Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024

Price target decreased by 7.6% to CN¥29.52

What Amoy Diagnostics Co., Ltd.'s (SZSE:300685) 33% Share Price Gain Is Not Telling You

Is Amoy Diagnostics Co., Ltd. (SZSE:300685) Worth CN¥22.0 Based On Its Intrinsic Value?

Now 24% overvalued

Investor sentiment improves as stock rises 20%

New minor risk - Share price stability

Amoy Diagnostics Co., Ltd. to Report Fiscal Year 2023 Results on Apr 16, 2024

Amoy Diagnostics Co., Ltd.(SZSE:300685) dropped from Shenzhen Stock Exchange Component Index

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Amoy Diagnostics Co., Ltd. to Report Q3, 2023 Results on Oct 24, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Amoy Diagnostics Co., Ltd. to Report First Half, 2023 Results on Aug 01, 2023

Amoy Diagnostics Co., Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 23 May 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CN¥35.47

Less than half of directors are independent

Consensus revenue estimates fall by 18%

Price target decreased to CN¥41.29

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Amoy Diagnostics Co., Ltd., Annual General Meeting, Jun 20, 2022

Amoy Diagnostics Co., Ltd. Announces Dividend, Payable on May 31, 2022

Amoy Diagnostics Co., Ltd. Approves Dividend for 2021

Price target decreased to CN¥82.96

High number of new directors

Amoy Diagnostics Co., Ltd. Announces the Profit Distribution Proposal for 2021

Price target decreased to CN¥93.33

Full year 2021 earnings: EPS and revenues miss analyst expectations

Now 22% undervalued after recent price drop

Consensus EPS estimates fall by 15%

Full year 2021 earnings: EPS and revenues miss analyst expectations

Amoy Diagnostics Co., Ltd. (SZSE:300685) announces an Equity Buyback for CNY 200 million worth of its shares.

Amoy Diagnostics Co., Ltd. and PREMIA Holdings (HK) Limited Announces the Commercial Launch of the AmoyDx® Pan Lung Cancer PCR Panel in Japan

Third quarter 2021 earnings released: EPS CN¥0.29 (vs CN¥0.21 in 3Q 2020)

Price target increased to CN¥105

Second quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.24 in 2Q 2020)

Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., and Precision Medicine Asia Co., Ltd. Announce the Approval of AmoyDx Pan Lung Cancer PCR Panel

Full year 2020 earnings released: EPS CN¥0.82 (vs CN¥0.63 in FY 2019)

New 90-day low: CN¥67.96

Amoy Diagnostics Co., Ltd. to Report Fiscal Year 2020 Results on Apr 13, 2021

New 90-day high: CN¥92.11

New 90-day high: CN¥87.26

New 90-day low: CN¥71.91

New 90-day low: CN¥72.29

Third quarter earnings released

New 90-day high - CN¥88.26

New 90-day high - CN¥79.53